NASDAQ:AADI - Aadi Bioscience Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $47.67
  • Forecasted Upside: 63.75 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$29.11
▼ -0.96 (-3.19%)

This chart shows the closing price for AADI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aadi Bioscience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AADI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AADI

Analyst Price Target is $47.67
▲ +63.75% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Aadi Bioscience in the last 3 months. The average price target is $47.67, with a high forecast of $51.00 and a low forecast of $45.00. The average price target represents a 63.75% upside from the last price of $29.11.

This chart shows the closing price for AADI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Aadi Bioscience.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/14/2021LADENBURG THALM/SH SHInitiated CoverageBuy$51.00Low
9/8/2021Piper SandlerInitiated CoverageOverweight$45.00High
8/30/2021HC WainwrightBoost Price TargetBuy$22.00 ➝ $47.00N/A
(Data available from 9/28/2016 forward)

News Sentiment Rating

0.01 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/2/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 1 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/28/2021

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Aadi Bioscience logo
Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancers patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in October, 2011 and is headquartered in Los Angeles, CA.
Read More

Today's Range

Now: $29.11
Low: $28.40
High: $29.11

50 Day Range

MA: N/A

52 Week Range

Now: $29.11
Low: $14.31
High: $49.80

Volume

7 shs

Average Volume

311,851 shs

Market Capitalization

$92.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67

Frequently Asked Questions

What sell-side analysts currently cover shares of Aadi Bioscience?

The following Wall Street analysts have issued research reports on Aadi Bioscience in the last year: HC Wainwright, LADENBURG THALM/SH SH, and Piper Sandler.
View the latest analyst ratings for AADI.

What is the current price target for Aadi Bioscience?

3 Wall Street analysts have set twelve-month price targets for Aadi Bioscience in the last year. Their average twelve-month price target is $47.67, suggesting a possible upside of 58.5%. LADENBURG THALM/SH SH has the highest price target set, predicting AADI will reach $51.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $45.00 for Aadi Bioscience in the next year.
View the latest price targets for AADI.

What is the current consensus analyst rating for Aadi Bioscience?

Aadi Bioscience currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AADI will outperform the market and that investors should add to their positions of Aadi Bioscience.
View the latest ratings for AADI.

How do I contact Aadi Bioscience's investor relations team?

Aadi Bioscience's physical mailing address is 9987 Carver Rd, Blue Ash, Ohio 45242-5550. The company's listed phone number is (513) 985-1920 and its investor relations email address is [email protected] The official website for Aadi Bioscience is www.aerpio.com.